The new generation of direct acting antivirals (DAA) for the treatment of chronic hepatitis C virus infection has revolutionized the previous scenario and has put the institutions under test because of the high cost of therapies. An analysis of what has happened over the last three years, especially in Italy, helps us understand how price negotiation has been managed, and what criteria were chosen at first to allow limited access on the basis of the need of patient care. This allows to focus on some important issues and to identify the challenges ahead in the near future.
|Numero di pagine||3|
|Rivista||RECENTI PROGRESSI IN MEDICINA|
|Stato di pubblicazione||Published - 2018|
All Science Journal Classification (ASJC) codes